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Porcine reproductive and respiratory syndrome virus (PRRSV) is a significant swine
pathogen which exhibits considerable sequence diversity. In an attempt to identify highly
conserved T-cell epitopes contained in proteins of this virus, we examined heptadecamer
peptides spanning the sequence of the PRRSV nonstructural proteins 9, 10 and 11, all of
them are highly conserved, for their ability to elicit a recall proliferative and interferongamma response in peripheral blood mononuclear cells obtained from pigs immunized
against the type-II PRRSV strain FL-12. These studies led to the identification of seven
peptides, two from each NSP 9 and NSP 10 and, three from NSP 11 that appear to
contain T-cell epitopes. Comparison of the amino acid sequence of these seven peptide
sequences to the analogous sequences from a diverse sample of type-II PRRSV strains
indicated that these sequences are highly conserved and thus contain highly conserved Tcell epitopes. The identified epitopes may be important in the formulation of
immunogens to provide broad cross-protection against diverse PRRSV strains.
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Chapter 1: General Introduction
Objective
The identification of T-cell epitopes in PRRSV is sparse and has been limited to
structural proteins. Two distinct regions on the GP5 amino acid sequence from PRRSV
genotypes I and II were found to contain T-cell epitopes based on their ability to
stimulate IFN-γ secreting cells (Diaz et al., 2009). In addition, one report has recently
reported the identification of four T-cell epitopes located on the membrane (M) protein of
PRRSV (Wang et al., 2011). Taken together, these reports illustrate an invigorated
interest in achieving a more detailed picture of the cell mediated protective immunity
against PRRSV. Several examples exist, in the case of other highly diverse and variable
RNA viruses such as hepatitis C virus (HCV) (Martin et al., 2004) and HIV (Gruters et
al., 2002), indicating that highly conserved, T-cell epitopes are responsible for a broad
protection based on CMI. Such conserved regions are often detected in nonstructural
proteins (NSPs) of these RNA viruses that are synthesized early during the life cycle of
the virus. These NSPs typically constitute structurally constrained, conserved proteins
involved in replication of the virus. If animals are preferentially immunized against these
conserved epitopes of NSPs, it is possible that such immunization could result in a highly
“pan-strain specific” protective immunity. This is the principle applied in the
development of several multi-epitope vaccines recently reported for “hard-to-immunize”
RNA viruses such as HCV (Martin et al., 2004) or HIV (Gruters et al., 2002; Yang et al.,
2002) and also against chronic hepatitis B virus infection (Depla et al., 2008).
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Accordingly, we selected a subset of PRRSV NSPs based on their functional role in viral
replication and virulence. The ORF1 (b) region of the PRRSV genome contains the NSPs
9, 10, 11 and 12 genes. The NSP 9 is the viral RNA-dependent RNA polymerase (RdRp)
required for genome replication and transcription and the NSP 10 encodes for helicase
function (Fang and Snijder, 2010). The main criteria used to select NSP 9, NSP 10 and
NSP 11 for this study was their highly conserved nature which is consistent throughout
the North American PRRSV strains, thus constituting good candidates for the
identification of T-cell epitope that could provide target antigens capable of eliciting
cross-protective immunity against PRRSV. To achieve this goal, overlapping
heptadecapeptides spanning the entire length of the PRRSV NSP 9, NSP 10 and NSP 11
were screened respectively using T-cell proliferation and IFN-γ ELISpot assays. Herein
we report the identification of T-cell epitopes mapping to these PRRSV NSPs. Two
distinct regions each in NSP 9 and NSP 10 and, three distinct regions in NSP 11 were
identified as putative T-cell epitopes. As expected, these epitopes were found to be highly
conserved among thirty-four North American PRRSV type-II sequences. Moreover,
sixty-five additional sequences analyzed to detect the conservation of those T-cell
epitopes also proved positive with a high percentage of conservation throughout the
North American PRRSV strain.

3

Chapter 2: Literature Review
Porcine Reproductive and Respiratory Syndrome Disease
Porcine reproductive and respiratory syndrome (PPRS) leads to respiratory disorder in
young pigs. It also causes severe reproductive failure and late abortions in sows. The
disease was first reported in 1987 in North America, and the causative agent was isolated
and characterized for the first time in Europe in 1991(Wensvoort et al., 1991) and one
year later in the United States of America (Collins et al., 1992). PRRS has now emerged
in the swine industries worldwide and has caused significant economic loss in the pork
industry worldwide (Neumann et al., 2005). The causative agent PRRS virus (PRRSV) is
a member of the family Arteriviridae which also comprises of other viruses such as
Equine Arteritis Virus (EAV), mouse lactate dehydrogenase elevating virus (LDV), and
Simian Hemorrhagic Fever Virus (SHFV) (Cavanagh, 1997).
PRRSV is also known as “Blue-Ear Pig” disease which is primarily transmitted via
aerosols. It affects mostly young sows and boars (Rossow, 1998). The important factors
responsible for the PRRSV infection in the matured pigs rely on the type of PRRS viral
strain, gestation period, breed, gender and immune status of the PRRSV infected sows.
PRRSV infected pregnant sows show clinical manifestations which include fever,
anorexia, lymphadenopathy, labored respiration, gross and microscopic lesions in the
lung, and reproductive failure characterized by delivery of weak/stillborn piglets
autolysed fetuses (Christianson et al., 1992; Hopper et al., 1992; Rossow et al., 1994;
Terpstra et al., 1991). PRRSV infection in neonatal pigs develops variable clinical signs
characterized by severe dyspnea and tachypnea (Cooper et al., 1995; Hopper et al., 1992;
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Rossow et al., 1994; Rossow et al., 1995; Wensvoort et al., 1991). Death rate of the
PRRSV infected neonatal pigs exceeds up to 100% (Rossow, 1998).
One of the important features of PRRSV infection is prolonged viremia in the infected
pigs and this may result in continuous shedding of virus for longer periods without
entering a latent stage. Tonsils, lungs and lymphoid organs are the major source of viral
RNA during the persistence of PRRSV infection in the infected pigs (Lamontagne et al.,
2003). Also, PRRSV RNA has been detected by RT-PCR in the semen of boars
evidenced in vivo at 92 days post infection (d.p.i) (Christopherhennings et al., 1995). In
postnatally infected pigs persistence of PRRSV has been reported for up to 150 days,
while naturally infected pigs contained virus even up to 210 days(Cho and Dee, 2006).
Porcine Reproductive and Respiratory Syndrome Virus
PRRSV is a small, enveloped and cytolytic virus with a size of 50-65 nm. This positivesense single stranded RNA virus carries a methylated cap at the 5’ end and a
polyadenylated tail at the 3’ end of its genome. PRRSV belongs to order Nidovirales,
family Arteriviridae, genus Arterivirus and its genomic length is about 15.4 kilobase
(Cavanagh, 1997; Conzelmann et al., 1993; Wu et al., 2001). It contains 9 open reading
frames (ORFs) among which ORF1a and 1b comprise about 80% of the genome and
encode for two polyproteins which, after translation, are proteolytically cleaved into 14
nonstructural proteins (NSPs), e.g., NSP1α, NSP1β and NSP2 to NSP12. Both NSP 9,
which encodes the viral RNA-dependent RNA polymerase (RdRp) and NSP 10, which
encodes a helicase, are responsible for the viral genome replication and transcription.
The RdRp domain is found in the C-terminal portion of replicase subunit, NSP 9, which
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contains an additional upstream domain of unknown function. PRRSV RNA helicases are
a diverse class of enzymes that uses ATP hydrolysis to unwind RNA duplexes in a 5’-to3’ direction in vitro. Like RdRp domain, helicase is part of a larger replicase subunit,
NSP 10, which also contains an N-terminal predicted zinc-binding domain comprising of
highly conserved 13 Cys and His residues. This particular domain can prove critical for
the in vitro ATPase and helicase activities of the protein. In addition to the core viral
enzymes (NSP 9 and NSP 10), the Nidovirus endoribonuclease (NendoU) domain has
been identified in NSP 11 and is N-terminally fused to another domain of unknown
function. It has been evidenced through reverse genetics that this particular domain of
NSP 11 plays an important role in the replicative cycle of all Arteriviruses (Bautista et
al., 2002; Fang and Snijder, 2010). Nedialkova et al has shown that recombinant PRRSV
NSP 11 exhibited broad substrate specificity in vitro (Fang and Snijder, 2010;
Nedialkova et al., 2009). It has also been demonstrated that the NendoU knockout
mutants remained capable of RNA synthesis that helped in the prediction that this
enzyme may not function in a Nidovirus-specific step of viral synthesis but rather targets
unknown cellular substrates(Fang and Snijder, 2010). ORFs 2a, 2b and 3-7 located at the
3’ end of the viral genome undergo posttranslational cleavage to produce PRRSV
structural proteins (Dea et al., 1996; Meulenberg et al., 1995; Wu et al., 2001). The
structural proteins are expressed from the 3’ end nested set of sub-genomic m RNA Abs
sharing the common leader sequence at the 5’ terminus (Meulenberg, 2000; Snijder and
Meulenberg, 1998). Glycoprotein 5 (GP5), membrane (M) and nucleoprotein (N)
encoded by ORFs 5-7, respectively, are known to be the major components viral particles
(Dea et al., 2000). The N protein interacts with viral genome to form the nucleocapsid. M
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interacts with GP5 to form a heterodimer which is essential for viral assembly since viral
particles are not released in the absence of either GP5 or M protein (Mardassi et al., 1996;
Wissink et al., 2005). The minor proteins in viral particles include ORF 2a, 3 and 4 and
they encode for GP2a, GP3 and GP4, respectively. These proteins interact with each
other and are assembled into the virion as a multiplex complex which is also involved in
viral infectivity (Wissink et al., 2005). ORF2b, otherwise called as envelope protein (E),
is embedded within the ORF2a (Wu et al., 2001).
In spite of the route of entry, productive infection occurs predominantly in alveolar
macrophages of the lung (Murtaugh et al., 2002). In vitro studies with the virus infection
in these cells have shown their ability to grow in primary cultures of alveolar lung
macrophages. PRRSV has a strong restricted cell tropism for certain subpopulations of
swine monocyte or, macrophage lineage, notably pulmonary intravascular macrophages,
subsets of macrophages in lymph nodes and spleen, and intravascular macrophages of the
placenta and umbilical cord (Duan et al., 1997; Lawson et al., 1997). In experimentally
infected boars, PRRSV can be detected by PCR in semen samples at 92 d.p.i
(Christopher-Hennings et al., 1995; Christopherhennings et al., 1995). Experimental
studies have shown that subclinical PRRSV infection can persist in the animals. Thus,
persistent infection of PRRSV plays a major role in PRRSV survival and transmission,
and will likely pose an obstruction in the PRRS control programs (Bilodeau et al., 1994;
Wills et al., 1997).
PRRSV grows well in the African monkey kidney cell MA-104 and its derivatives
MARC-145, CL-2621 and CRL11171 (Benfield et al., 1992; Collins et al., 1992; Kim et
al., 1993; Meng et al., 1994; Meng et al., 1996). They can also be grown in porcine
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alveolar macrophages (PAM) cultures (Wensvoort, 1993; Wensvoort et al., 1991). Swine
testis (ST) cells were also reported to support PRRSV replication (Plana et al., 1992).
Receptor-mediated endocytosis helps the PRRSV to enter into the host cells (Kreutz and
Ackermann, 1996; Nauwynck et al., 1999). Some strains of PRRSV do not propagate in
all the cell lines showing variations in their susceptibilities as a result, this indicates the
existence of PRRSV variants. Thus, both PAM and other cell lines should be used when
attempting virus isolation from clinical samples. The PRRSV virion after attachment with
the host cell receptors enters into the cells in a clathrin-dependent manner. The viral
genomic RNA transfected in the BHK-21 cells lead to the production of infectious virus.
Interestingly, cell receptors play a major role as a determinant in PRRSV cell-tropism.
(Meulenberg et al., 1998; Nielsen et al., 2003).
Two independent PRRSV receptors heparin sulfate and porcine sialoadhesin (PoSn) have
been identified in PAM. On the alveolar macrophages, the viral protein heterodimer GP5M interacts with the porcine cell surface receptor porcine sialoadhesin. However, this
interaction prevents virus entry into the cells irrespective of the binding of viral particles
to the cell surface receptors (Delputte et al., 2005; Delputte et al., 2002). In the meantime,
sialoadhesin is responsible for both viral attachment and internalization. During
uncoating of the virus, it functions together with CD163 (Delputte et al., 2005; Duan et
al., 1998; Van Gorp et al., 2008; Vanderheijden et al., 2003). Minimal levels of PoSn
expression by the non-activated monocytes may play important role in susceptibility to
PRRSV infection (Kimman et al., 2009).
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Genetic and Antigenic diversity among various PRRSV strains
PRRSV has been clinically, genetically and antigenically divided into two types which
include European (EU-type-I) and North American (NA-type-II) (Mardassi et al., 1994;
Meng, 2000; Meng et al., 1994; Meng et al., 1995b; Morozov et al., 1995; Murtaugh et
al., 1995). Both of them cause very similar clinical signs in swine irrespective of their
genetic and serological differences.
Genetic diversity
PRRSV is genetically heterogeneous by nature (Meng, 2000). The two genotypes
resemble 60% to each other based on their overall nucleotide homology although their
biological characteristics are very similar (Kim and Yoon, 2008). The relative nucleotide
sequence identity between the US isolates and Lelystad is 45.7% in ORF1b, 65-67% in
ORF2, 61-64% in ORF3, 63-66% in ORF4, and 61-63% in ORF5 (Meng et al., 1995a;
Meng et al., 1995b). ORFs 6 and 7 genes are relatively conserved among the US isolates
or among the EU isolates, but extensive genetic variation was observed in the ORFs 6
and 7 genes between EU and US isolates (Meng et al., 1995a). It has been demonstrated
by certain experimental analysis of the nucleotide sequence of ORFs 2-7 of 10 US
PRRSV isolates that the genetic distance ranges from 2.5-7.9% and is about 35%
between LV and the US isolates (Kapur et al., 1996). GP5, the major envelope protein is
highly variable and is only 50-55% identical between the two genotypes (Mardassi et al.,
1995; Meng et al., 1995b; Nelsen et al., 1999). This variability is caused due to greater
induction of neutralizing antibodies (NAbs) which causes exposure to selective antibody
pressure. The ORF1 genomic sequence also differs extensively between the US and the
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EU strains by 55% nucleotide sequence identity (Allende et al., 1999; Nelsen et al.,
1999). ORF1b is more conserved than ORF1a and shares 63% nucleotide sequence
identity with that of LV (Meng, 2000). The pathogenic NA PRRSV isolate 16244B has
similar sequence homology with the LV with only 63.4% nucleotide identity. ORF1a
polyprotein containing the non-structural part has major differences which shared 47%
amino acid identity over 2503 residues of the six NSPs encoded. The greatest diversity is
found in the NSP2 genome. About 32% amino acid identity is shared with the NSP2
region of LV. It also contains 120 additional amino acids in the central regions. NSPs
encoded by the 5’-proximal and central regions of ORF1b have 66-75% amino acid
identity. In addition, the ORF1a-1b frame shift region of 16244b has 98% nucleotide
identity with LV (Allende et al., 1999; Meng, 2000).
Current studies have shown that EU-PRRSV is also found in other parts of the world
such as Canada (Dewey et al., 2000). Meanwhile, type-II PRRSV has also been found in
European region via introduction of live vaccine (Nielsen et al., 2001; Nielsen et al.,
2002; Storgaard et al., 1999). It has been noticed that EU-like PRRSV isolates have
slowly emerged in the US herds (Fang et al., 2007; Ropp et al., 2004). The remarkable
feature in EU-PRRSV which differentiates it from the NA-PRRSV is the deletion of 51
nucleotide in its NSP2 region (Fang et al., 2007). PRRSV genetic heterogeneity has
increased over time and co-circulation of different variants and their maintenance may
contribute to heterogeneity. This can evident from the analysis of the nucleotide sequence
similarity that has decreased up to 4.4% range in between the years 1995 and 2000
(Prieto et al., 2009).
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The concept of quasispecies variation was demonstrated by sequence analysis of various
PRRSV strains which highlighted the strategies of PRRSV infection spread among
interspecies (Goldberg et al., 2003). It has also been reported that there are evidence for
quasispecies evolution and emergence of a virus subpopulation during utero infection of
pigs with a PRRSV isolate (Rowland et al., 1999). The importance of having a
quasispecies population during virus infection will affect vaccine efficacy and may lead
to vaccine failure (Domingo et al., 1998; Domingo and Holland, 1992; Duarte et al.,
1994). Therefore, future investigation in this regard can prove beneficial in the field o
PRRSV immunology.
Other important factors leading to the genetic divergence in PRRSV includes the lack of
proof-reading activities of RdRp. RNA recombination is also another serious factor
leading to the PRRSV polymorphism (Meng, 2000). Recombination of viral particles
containing chimeric ORF3 and ORF4 proteins of PRRSV genome were identified during
co-infection of two PRRSV isolates in MA-104 cells which showed an estimated
frequency of recombination from <2 to 10%. Moreover, sequence analyses of various
field isolates of PRRSV have revealed that RNA recombination of PRRSV can also occur
in nature(Yuan et al., 1999).
Antigenic Variation
Antigenic variations among various isolates of PRRSV have been well documented
(Meng, 2000). It has been reported about the differential activity of the monoclonal
antibodies (MAbs) using the two genetic types of PRRSV, EU- and NA- types. Two
MAbs VO17 and EP147 to N protein recognized a conserved epitope in US and EU-
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PRRSV isolates. The N-protein MAb SDOW17 works as a common MAb to both NA
and EU-PRRSV isolates indicating the presence of a common conserved epitope (Nelson
et al., 1993). However, four other MAbs of PRRSV N-protein responded to NA-PRRSV,
confirming their strain-specificity (Nelson et al., 1993). Six MAbs raised against British
isolate of PRRSV recognized EU isolates but did not react with US isolates (Drew et al.,
1995). Five anti-GP5 MAbs from a Canadian isolate were unable to react with LV
(Pirzadeh and Dea, 1997). The reactivity of MAbs against GP3, GP4 and N proteins with
EU- and US-PRRSV isolates revealed antigenic differences both within the isolate as
well as between the isolates (Katz et al., 1995; Wieczorek-Krohmer et al., 1996).
The degree of antigenic variation within each PRRSV type is highly considered during
the design of future vaccines. A multivalent vaccine comprising of multiple antigenically
distinct strains of PRRSV can prove as the most promising candidate for the next
generation of vaccines (Meng, 2000).
Immune Response
Development of a weak and delayed protective immunity against PRRSV infection leads
to prolonged acute and persistent infection in pigs. The acute post-infection is followed
by the presence of clinical symptoms and abundant replication in target cells such as
alveolar macrophages. Acute post-infection is characterized by high viral load in tissues
and by the presence of cell-free (serum associated) viremia for one month. The persistent
phase of PRRSV involves low level of viral replication. 100% viral clearance was seen in
at least more than 150 days post-infection. A period of two months post-infection for
effective contagion to other animals has been seen early after exposure a vigorous anti-

12

PRRSV antibody response at 7-9 days post-infection was detected by ELISA. Antibodies
with PRRSV-neutralizing activity appear only at later post-infection times (≥ 4 weeks),
leading to polygonal B-cell activation. Presence of total antibodies in serum during early
post-infection viremic phase of PRRSV infection indicates about the inability of
antibodies to play a role in protection against PRRSV infection. Anti-PRRSV antibodies
constitute a non-protective but deleterious response. Due to slow, irregular appearance of
PRRSV-NA after PRRSV exposure, it was able to prevent the appearance of viremia.
Infected pigs develop a T-cell mediated response at 4 weeks PI indicating a CD4 T-cell
response. Specific IFN-γ production by T-cells (CTL specific response) showed a delay
in the response similar to the one observed with NA. Mostly infected pigs shed viral
infection at approximately 3-4 months of post-infection. Therefore, it is difficult to gain a
complete solid protection against PRRS infection (Lopez Fuertes et al., 1999; Lopez and
Osorio, 2004; Meier et al., 2003). Moreover, very little information is known about the
PRRSV structural and nonstructural proteins that can provide protective immunity
against PRRSV infection.
Innate immunity
Host innate immunity exhibits a crucial role in the PRRSV immunology. Type-I
interferons (e.g., IFN-α/β) display innate protection against PRRSV infection (Seth et al.,
2006). Various experimental studies have reported that PRRSV is sensitive to the
antiviral effects of type-I IFN (Buddaert et al., 1998; Lee et al., 2004; Miller et al., 2004).
In vitro studies have shown that upon pretreatment of PAM culture with porcine IFN-α
prior to PRRSV infection has resulted in significant reduction in virus titer (Albina et al.,
1998; Buddaert et al., 1998; Lee et al., 2004). The sensitivity of PRRSV to IFN effects is
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PRRSV isolate-dependent(Lee et al., 2004). Several studies have revealed that IFN-α
helps in the clearance of viral activity in infected pigs. PRRSV infection alone is unable
to IFN-α. Interestingly, pigs which were infected with Corona virus prior to PRRSV
infection, resulted in potential induction of IFN-α, thereby, deliberately reducing viral
titers (Buddaert et al., 1998). It has also been evidenced that PRRSV is a poor inducer of
type-I IFNs (Albina et al., 1998; Lee et al., 2004; Miller et al., 2004). Moreover, it has
been suggested that PRRSV may actively suppress type-I IFN production (Albina et al.,
1998). PRRSV infection in pigs rarely elicit IFN-α in their sera and lung secretions
(Albina et al., 1998). In vitro, PRRSV infection to PAM cells do not show marked
induction in the IFN-α production (Albina et al., 1998; Lee et al., 2004). Also, MARC145 infected with PRRSV has shown alteration in the production of both IFN-α/β m RNA
Abs in response to double stranded RNA stimulation (Miller et al., 2004). The viral
particles important for the potent elicitation of type-I interferons have not been
indentified clearly. Recent works have been published to show that few PRRSV proteins
such as NSP1, NSP2, NSP4, NSP 11 and N-protein are involved in IFN-β production
(Beura et al.). It has also been proved that PRRSV infection inhibited function of IFN-β
promoter stimulator 1 (IPS-1) molecule of the retinoic acid –inducible gene I (RIG-I) or
TLR-independent dsRNA signaling pathway which resulted in the inhibition of synthetic
dsRNA-induced IFN-β production and IRF3 nuclear translocation (Luo et al., 2008). An
intriguing observation is that the production of IFN-γ response in swine serum lasts
approximately for 3 weeks (Wesley et al., 2006). Serum levels with increased amount of
viral load and inhibition of PRRSV replication by IFN-γ lead to the conclusion that IFN-γ
may have a crucial role in the PRRS disease (Bautista and Molitor, 1999; Gaudreault et
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al., 2009; Loving et al., 2008). Generally early production of IFN-γ could be due to the
activation of natural killer (NK) cells and alveolar macrophages. These pathways have
not been identified yet in PRRSV.
Acquired immunity
The delayed immune response developed for protection against viral infection is a
debated issue. It takes at least 3 months of time period to develop immunity against
natural infection. Moreover, this does not confer a solid protection to prevent reinfection, especially caused by heterologous PRRSV strains (Murtaugh et al., 2002;
Zuckermann et al., 2007). Experimental studies have shown that gilts infected with an
US-PRRSV type isolate and challenged with EU-PRRSV isotype (Lelystad virus) late in
gestation period provided partial protection against the transplacental infection, whereas
all the gilts challenged with the homologous virus were completely protected (Lager et
al., 1999). These studies provided information about the existence of the partial
heterologous protection and also indicate that common epitopes are likely involved in
protection against EU- and US-PRRSV strains. As a result, it has become important to
understand the acquired immunity in spite of a broad genetic and antigenic variation of
circulating strains of PRRSV which can help to induce IFN-γ to provide a protective
immunity against PRRSV infection. Moreover, it has been suggested by Diaz et al., that
the different capacity of PRRSV strains to induce protective immunity depends on their
different capacity to induce a strong cellular, in particular IFN-γ, immune response(Diaz
et al., 2006).
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Humoral immunity
An important aspect of PRRSV infection is the delayed development of NAbs. PRRSVspecific antibodies begin to appear in the infected pigs as early as 7-10 d.p.i with a low
viral titer (Loemba et al., 1996; Plagemann, 2006). The main feature of the onset of
humoral immune response consists of early production of low leveled non-NAbs
followed by delayed NAbs between 2-4 weeks PI (Labarque et al., 2004; Loemba et al.,
1996). It has been demonstrated that there may be a high induction of NAbs and virus in
vivo, but on experimental basis both NAbs and non-NAbs lead to PRRSV replication in
macrophages. As a result, these antibodies can bind to the virus and internalize the viral
particles into macrophages (Diaz et al., 2006). In vitro studies have demonstrated PAM
and MARC-145 cells are prone to secondary PRRSV infection even after the
development of early antibodies from the first infection (Nelson et al., 1994; Yoon et al.,
1994; Yoon et al., 1995). Antibodies which are passively transferred from pregnant sows
to the off springs provide protection against PRRSV infection and help to block
transplacental PRRSV infection (Lopez et al., 2007; Osorio et al., 2002). This shows
antibodies are important in protecting swine against re-infection with PRRSV. However,
addition of NAbs helped in the suppression of viral infectivity in the already infected
PAM and MARC-15 cells. This was achieved by blocking viral attachment and
internalization (Delputte et al., 2004). Generally, NAb were first detected in serum at
about 4 weeks PI (Lopez and Osorio, 2004; Mateu and Diaz, 2008). Thus, inefficiency of
NAbs and early antibodies towards developing a solid protection confirmed that
antibodies alone cannot protect the pigs against PRRSV infection. It was further
confirmed from experimental studies that induction of viral infection and replication is
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further supported by the antibody production. NAbs pass from mother to their off springs
via colostrums and milk to provide protection against PRRSV infection (Yoon et al.,
1996). Importantly, there is a chance of NAbs getting transferred from sows to their
offspring maternally through the colostrum and milk. Thus, it provides sterilized
immunity in the new-born piglets. Labarque et al., from his findings has suggested one
most important role of NAbs in virus clearance related with the clearance of PRRSV
from the lungs of infected pigs and the appearance of neutralizing antibodies in sera and
bronchoalveolar fluids (Labarque et al., 2004).
PRRSV nucleocapsid protein carries the highest immunogenic properties among all the
PRRSV proteins. High levels of anti-N antibodies could be detected at 7 d.p.i, but these
do not provide neutralizing property and hence, do not correlate with protection against
PRRSV infection. However, these are unable to neutralize the virus. It has been reported
that viral epitopes capable of inducing NAbs resides on the GP2a, GP3, GP4, GP5 and M
proteins (Meulenberg et al., 1997; Ostrowski et al., 2002; Plagemann et al., 2002; Yang et
al., 2000). Among these, NAbs against GP5 of both European and North American
PRRSV happen to be most relevant for protection as major neutralization epitope of
PRRSV are located in the middle of the GP5 ectodomain (Plagemann et al., 2002). The
neutralizing activity of MAbs against GP5 has been known to show stronger activity than
that of antibodies to the GP4 (Weiland et al., 1999). GP5-based neutralizing epitope of
NA-PRRSV denoted as Epitope B is highly conserved (Ostrowski et al., 2002;
Plagemann, 2004). An additional immunodominant non-neutralizing decoy epitope,
epitope A, present in the upstream of the epitope B interferes with the immune response
to epitope B (Fang et al., 2006). It has been shown that the proximity of epitopes A and B

17

is a compulsory requirement in delayed NAb response (Fang et al., 2006). The flanking
N-linked glycosylation sites on both sides of the epitope B exhibits poor immunogenicity
of the epitope B. Hence, it leads to an early and high induction of NAbs response as
compared to the wild-type virus (Mateu et al., 2006).
It has also been reported that the M protein contain two neutralizing epitopes. It has been
shown that the GP5-M interaction has been used for the construction of a DNA vaccine
but NAbs titers induced by this vaccination protocol were low (Jiang et al., 2006).
However, GP3 and M protein NAbs remain unidentified yet. Interestingly, the
neutralizing ability of GP3-specific antibodies has been mentioned due to its
characterization as a NSP in some NA-PRRSV isolates as well as a structural protein in
some EU-PRRS isolates (Meulenberg and Petersen-den Besten, 1996). Also, EU-PRRSV
contains a neutralizing epitope in its ORF4 region (Vanhee et al.).
Cell-mediated immunity
Cellular mediated immunity (CMI) plays an important role in PRRSV immunology.
Previous studies have shown that pigs recovering from experimental PRRSV infection
develop strong lymphocyte proliferative and NA responses after four weeks PI (Bautista
and Molitor, 1997; Lopez Fuertes et al., 1999). T-cell responses were mainly categorized
by type-I cytokine expression phenotype with IFN-γ as the major cytokine and, to a lesser
extent, IL-2 (Lopez Fuertes et al., 1999). These kinds of cytokine expression are
generally identified between 4-12 weeks PI (Bautista and Molitor, 1997; Lopez Fuertes et
al., 1999). Post-vaccination with US-PRRSV modified live vaccine have led to the virusspecific IFN-γ secreting cells which appeared first in the third week post-vaccination and
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increased the number of peripheral blood mononuclear cells (PBMCs) at 48 weeks postvaccination (Meier et al., 2003). The double positive cells (CD4+CD8+) present in the
porcine immune system are responsible for IFN-γ secretion (Meier et al., 2003). An
identical immune response with delayed development of PRRSV-specific IFN-γ secreting
cells was evident after infection or vaccination with European strains of PRRSV (Diaz et
al., 2005; Diaz et al., 2006). However, a live attenuated PRRSV vaccine that induced
high IFN-γ secreting cell frequencies protected pigs against viremia. IL-10 levels have
also been observed to inversely correlate with the IFN-γ responses. These results include
the involvement of a strong T-cell immunity, IFN-γ and IL-10 in the development of
immunity against PRRSV(Diaz et al., 2006). This indicates towards the switching over of
the immune response from Th1-Th2-mediated immune response. However, GP2(a/b),
GP3, GP4, GP5, M and N proteins of PRRSV were examined individually to validate
their capability to induce T-cell proliferation. Upon individual expression of these ORFs
using vaccinia virus system it was revealed that the M protein was the strongest inducer
of proliferation (Bautista et al., 1999; Jiang et al., 2007a; Jiang et al., 2007b; Lopez
Fuertes et al., 1999). There is a possibility that PRRSV may interfere with correct antigen
presentation and activation of T lymphocytes. PRRSV caused down-regulation of the
expression of major histocompatibility complex (MHC)-I in dendritic cells (DCs), in
spite of its correlation with the impaired proliferative responses in the mixed leukocyte
reaction (Loving et al., 2007). Expression of MHC-I, MHC-II and CD14 was downregulated in monocyte-derived DCs infected with infectious PRRSV (Wang et al., 2007).
Decreased proliferative responses were observed when infected DCs were used with
syngeneic or allogeneic lymphocytes. This again suggests that infected DCs present
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antigens less efficiently (Wang et al., 2007).

By altering the cytokine patterns of

macrophages and dendritic cells, as well as by modifying the expression of molecules
involved in antigen presentation PRRSV can down-regulate the innate immune response
(Mateu and Diaz, 2008). It has been noted that PBMCs isolated from infected pigs upon
treatment with CD4 and MHC class-II antibodies tend to reduce around 85% in the T-cell
proliferation (Lopez Fuertes et al., 1999). This led to a conclusive remark that CD4+ Tcells are specifically induced during T-cell proliferation. In fact, these infected PBMCs
showed greater IL-2 and IFN-γ response in comparison to IL-4 and IL-10. This
demonstrates that the CD4+ T-cells predominantly function in CMI response (Lopez
Fuertes et al., 1999).
ELISpot technology is a widely used assay to detect the CMI response against PRRSV
infection. These can be well predicted by estimating the IFN-γ secreting cells (IFN-γSC) in the PBMCs at 14 d.p.i. The frequency of IFN-γ-SC increases to its maximal levels
at 28 d.p.i and then slowly declines (Diaz et al., 2005; Diaz et al., 2006; Xiao et al., 2004;
Zuckermann et al., 2007). Alternate reports have conveyed that IFN-γ-SC remain
undetected until 8-10 weeks PI. But its frequency gradually increases by 48 weeks PI and
remains stable until 690 d.p.i (Meier et al., 2003). However, the ability of PRRSV to
induce IFN-γ-SC is comparatively low and delayed (Meier et al., 2003).
For most of the proteins T-cell epitopes have not yet been identified at amino acid level.
Consequently it is unknown whether conserved T-cell epitopes might provide crossprotection against different PRRSV strains. Determination of T-cell epitopes is an
expensive and cumbersome task due to the lack of a systematic approach based on the
synthesis and testing of large sets of overlapping peptides. Various strategies have been
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used to determine the PRRSV T-cell epitopes only in structural proteins. ELISpot assay
has been used recently by Vashisht et al., which helped them to identify two distinct
regions (amino acid residues 117-131 and 149-163) on GP5 of the North American
genotype of PRRSV that appeared to contain immunodominant T-cell epitopes (Vashisht
et al., 2008). Moreover, bioinformatics approach along with the ELISpot assay has helped
Diaz et al., group to detect two distinct regions on the GP5 amino acid sequence from
PRRSV genotypes I and II (Diaz et al., 2009). In addition, one report has recently
reported the identification of four T-cell epitopes located on the membrane (M) protein of
PRRSV(Wang et al., 2011). Taken together, these reports illustrate an invigorated interest
in achieving a more detailed picture of the cell mediated protective immunity against
PRRSV. Several examples exist, in the case of other highly diverse and variable RNA
viruses such as hepatitis C virus (HCV) (Martin et al., 2004) and HIV (Gruters et al.,
2002), indicating that highly conserved, T-cell epitopes are responsible for a broad
protection based on CMI. Such conserved regions are often present in the NSPs of these
RNA viruses that are synthesized early during the life cycle of the virus. These NSPs
typically constitute structurally constrained, conserved proteins involved in replication of
the virus. Thus, it has become essential to determine T-cell epitopes in those proteins and
vaccinate the PRRSV infected pigs with those conserved epitopes to develop “pan-strain
specific” protective immunity.
Vaccine Development against PRRS disease
Multiple vaccines against PRRSV infection are available commercially available. These
include inactivated-vaccines, modified-live vaccines, DNA vaccines and recombinant
DNA vector vaccines (Kimman et al., 2009). Current vaccines against PRRSV have
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several drawbacks. Modified live vaccines protect against homologous isolates but
generally have a limited effect against, challenge with heterologous viruses. Live PRRSV
vaccines provide partial protection against clinical disease but do not prevent infection.
Also, it can revert to virulence. Attenuated vaccines work similar to natural PRRSV
infection with low NA production. Killed vaccines have proved less effective in
prevention of both infection and disease. NA epitopes have also been developed to
generate new vaccines for protective response. At the same time, onset of IFN-γ inducing
CTL-response as well as CD4 T helper immune response as delayed immune response
may provide protective immunity. Both NA and virus-specific IFN-γ producing cells
have played important role in the designing of vaccines (Lopez and Osorio, 2004; Osorio
et al., 2002; Zuckermann et al., 2007). It has been reported that PRRSV-NA helps in the
prevention of infection of pregnant sows as well as transplacental infection (Osorio et al.,
2002). A killed vaccine inducing NAbs failed to protect pigs against an in vivo challenge
with the virus (Zuckermann et al., 2007). These pigs displayed a secondary neutralizing
antibody response upon challenge inoculation, thus suggesting the inefficiency of recall
response to provide full protection.
The inactivated-vaccines contain adjuvant. Killed-vaccine has failed to provide crossprotection against PRRSV infection. This was highly evident from the clinical signs,
reproductive failure, constant magnitude of viremia in semen among homologous strains
and congenital infection in the off springs. Also it remained unaffected in the sows and
boars (Scortti et al., 2007). Administration of killed-vaccine in boars did not change and
magnitude of viremia and shedding of virus in semen even against homologous challenge
(Nielsen et al., 1997).
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Modified-live vaccines (MLVs) have shown greater effectiveness in reducing disease
probability, and also during viremia and virus shedding. Protection by modified live
vaccines has shown solid protection against clinical disease induced by homologous
infection while the level of protection induced by MLVs against heterologous strains is
variable and substandard (Meng, 2000). However, MLVs were incapable to provide long
term protection against PRRSV infection (Christopher-Hennings et al., 1997; Diaz et al.,
2006; Labarque et al., 2004; Martelli et al., 2007; Okuda et al., 2008; Prieto et al., 2008;
Zuckermann et al., 2007). Simultaneously, MLVs prepared by targeting GP5 provided
complete protection against PRRSV (Labarque et al., 2004). It has been examined with
the so-called therapeutic vaccine intervention that it was unable to eliminate wild-type
PRRSV, but it significantly reduced the number of pigs persistently infected with a
homologous strain, but not pigs persistently infected with a heterologous strain (Cano et
al., 2007a; Cano et al., 2007b). Live-attenuated PRRSV vaccine (Ingelvac PRRS MLVR)
has been examined to check the adjuvant effects of several adjuvants on its protective
efficacy against PRRSV infection. Co-administration of IL-12 significantly helps in the
induction of the cell-mediated immune response to MLV vaccine as compared to MLV
alone (Charerntantanakul et al., 2006).
Various recombinant virus vector systems such as live attenuated vaccine-based Pseudo
rabies virus recombinant (strain Bartha)(Qiu et al., 2005), replication-defective
adenovirus recombinants(Jiang et al., 2008) and Mycobacterium tuberculosis strain
BCG(Bastos et al., 2004) has been used against PRRSV infection to induce immunity to
PRRSV. All the above data available so far suggest that all structural proteins of the virus
are essential for the production of infectious virus. Role of nonstructural proteins (NSPs)
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in the field of PRRS immunology has not been implemented yet. Their functional and
structural constraints can make many changes in the development of vaccine against
PRRSV. As NSPs are highly conserved among the various strains of the homologous as
well as heterologous genotypes, they can prove beneficial in cell-mediated immune
response. A safe, universal and efficient vaccine can provide a core protection to treat
PRRS affected pigs. The first priority depends on the detection of B- and T-cell epitopes
involved in the development of protective immunity. Neutralizing epitopes have been
established definitively but very little is known about T-cell epitopes, although T-cell
responses to individual PRRSV polypeptides have been reported in virus-infected
animals. The most important criteria performing this kind of experiment involve the
genome conservation of those epitopes in both European and American strains
(heterologous protection) as well as among the homologous strain (within American or,
European) of PRRSV(Bautista et al., 1999). The next important requirement is the
involvement of the components of the virion or viral genome responsible for viral downregulation or modulation of the swine immune system. The importance of a universal
vaccine not only includes immunological properties but, also the characteristics of the
strain, relationship between the immunopathological properties and genetic diversity
matters a lot (Mateu and Diaz, 2008). The third criteria incorporate the avoidance of the
possibilities of reversion of a viral strain in to virulence and also minimal transmission of
the vaccine strain between pigs. The obvious way to avoid this kind of possibilities is by
using non-replicating vaccines which are again questionable on their ability to induce
NAbs and adequate cell-mediated immune responses (Zuckermann et al., 2007). Subunit
or vector-based vaccines and inclusion of adjuvant can take active replacement on these
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parameters. The last important thing is the development of a differential vaccine. An
extensive study of essential and non-essential parts of the viral genome has not been
performed. The occurrence of natural variants with deletions in NSP2 indicated the
purpose of NSPs as better targets in the designing of these kinds of vaccines (Fang et al.,
2004).
Thus, it has become important to detect the T-cell epitopes and prepare a vector-based
universal vaccine against PRRSV infection. In addition, it is necessary to construct
vaccines that provide protection in both homologous and heterologous strains against
PRRSV infection.
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Chapter 3: Materials and Methods
General experimental design
Figure 1 illustrates the experimental design used in this study to identify T-cell epitopes
in PRRSV nonstructural proteins NSP 9, NSP 10 and NSP 11. To immunize the
principal group against PRRSV FL-12 animals were initially infected with a single
intramuscular injection of 106.5 TCID50 of PRRSV FL-12 followed by two additional
boosters of the same dose of PRRSV FL-12 given several weeks apart (see
below)(Osorio et al., 2002). The first booster was administered emulsified in Freund’s
complete adjuvant and the second was administered in incomplete Freund adjuvant. The
screening tests for NSP 9 and NSP 10 were performed independent of each other at
different time points and with different sets of pigs. To screen the NSP 9 peptides for
their ability to stimulate a recall T-cell response, a total of sixteen 4-5 weeks old,
Landrace x Large White were obtained from a PRRSV-free farm. Eight of those animals
were immunized against PRRSV and the other eight were used as non-immune
specificity controls. The first booster of the principal group was administered at 21 d.p.i
and the second at 96 d.p.i. For NSP 10 screening, we used a total of six mixed-breed
animals (same farm of origin, age, and genetic background as previous experiment, 4
PRRSV-immunized principals and 2 uninfected controls). In this case the first booster
was administered at 57 d.p.i and the second at 114 d.p.i. For both NSP 9 and NSP 10
experiments, starting at day 7 d.p.i and for the entire length of immunization in each
case, blood was collected weekly for the following assays: 1) confirmation of viral
infection parameters (viremia, T-cell proliferation and IFN-γ secreting cells by ELISpot)
and 2) testing the set of peptide pools as well as to confirm individual peptides. NSP 11
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experiments were conducted using cryopreserved PBMCs isolated during NSP 10
animal experiments.
For, NSP 9, NSP 10 and NSP 11 experiments, the animal groups were separately housed
in isolated bio-safety level 2 (BL-2) rooms to avoid cross-contamination. All the rooms
were well-ventilated and supplied with standard diet ad libitum and proper waste
disposal systems to avoid cross-contamination at all times.
Virus strain
To immunize the principal animals we used PRRSV FL-12 strain, which is a highly
pathogenic PRRSV type II strain derived from the infectious clone of PRRSV NVSL 977895 (Truong et al., 2004) (GenBank accession no. AY545985).
Isolation and cryopreservation of peripheral blood mononuclear cells (PBMCs)
Ten ml of whole blood was collected in a 5mM heparin tube and PBMCs were isolated
by density gradient

centrifugation using the Lymphocyte Separation Media

(Cellgro:Mediatech; cat # 25-072-CV) as previously described were washed using
Hyclone RPMI media without 10% fetal bovine serum (FBS, SAFC; cat # 12003C). Then
RPMI (10% FBS) was added to the isolated PBMCs obtained and the number of cells
were counted using haemocytometer. Purified PBMCs were used for the T-cell
proliferation assay. The purified PBMCs were also cryopreserved at a concentration of
3x107 viable cells/ml for ELISpot assay (Kreher et al., 2003). Pigs were bled once every
week for testing the set of peptide pools as well as to confirm individual peptides.
Cryopreservation of PBMCs was done at different time points including the first and
second post booster doses.
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Synthesis of PRRSV NSP 9, 10 and 11 synthetic peptides
Three libraries of synthetic heptadeca peptides, with a 9 amino acid overlap,
encompassing the entire sequence of NSP 9 (n=79, encompassing 646 aa), NSP 10
(n=54, encompassing 441 aa) and NSP 11 (n=27, encompassing 223 aa) were obtained
from NEO Peptide (Massachusetts) (Table 1). These peptides were used at a working
concentration of 3mg/ml. Initially, these peptides were used in the form of peptide pools,
each pool consisting of four overlapping 17-mer peptides located consecutively in the
respective gene sequence (each peptide concentration 20ug/ml). Peptides from
responding peptide pools were screened individually for the identification of all
individual peptides eliciting immunogenic responses and hence, possessing potential for
being T-cell epitopes. Twenty NSP 9, fourteen NSP 10 and seven NSP 11 peptide pools
were prepared for the T-cell epitope mapping study (Table 1).

T-cell proliferation Assay
PBMCs were obtained after thorough centrifugation using Lymphocyte Separation Media
(Cellgro:Mediatech; cat # 25-072-CV ). Cells were counted using a haemocytometer to
estimate the number of PBMC used to perform the in vitro proliferation assay. Cells at a
concentration of 4 x 106cells/ml in RPMI medium with 10% FBS were used for the assay.
A volume of 100µl cell suspensions was added to 100µl of synthetic peptides at a total
concentration of 20µg/ml adjusted in RPMI (10% FBS) and placed in the wells of 96well U-bottom plate. Plates were incubated for 48 hours at 37°C in 5% CO2. Twenty
microliters of [3H] Thymidine (corresponding to 1µCi per well; M P Bioquote) prepared
in cloning medium was added into each well. The plate was incubated for 16 hours at
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37°C. Cells were harvested using a PerkinElmer filtermate harvester. [3H] Thymidine
incorporation was measured using a scintillation counter (PerkinElmer 1450 LSC). Two
rounds of T-cell epitope screening were performed using this assay. The first round of
screening was performed using the peptide pools and in the second round the positively
responding (proliferating) peptide pools were checked for the T-cell proliferating activity
induced by individual peptides. A peptide or pool was considered likely to contain a Tcell epitope on the basis of stimulation index: the frequency of the proliferating cells in
response to the peptides which is higher by ≥ 2 folds than the control cells (media only)
alone (Vashisht et al., 2008). These experiments were repeated at least three times for all
the three NSP 9 and NSP 10, except NSP 11 proteins. Ten microgram per ml of
Concanavalin A was used as positive controls to validate the proliferation ability of the
cells cultured with peptides in all cases (principals and control animals).
IFN-γ ELISpot Assay
The PRRSV-specific IFN-γ ELISpot assay was previously studied and well established to
detect T-cell epitopes (Diaz et al., 2009; Vashisht et al., 2008). Ninety-six well Millipore
plates with PVDF membrane were selected to perform this assay (reference). To pre wet
the membrane, 15μl 70% ethanol was added to each well and incubated at room
temperature for 30 seconds. Primary antibody (porcine IFN-γ P2G10; BD Biosciences
Pharmingen, 50μl at 10μg per ml concentration) was added to each well and incubated
overnight at 4⁰C. The plate was washed six times with 0.05% sterile PBS-Tween20 and
blocked with 150μl PBS-BSA 1%. It was then incubated at 4⁰C overnight. The plate was
then washed with sterile PBS once and in each well 5 x 105 PBMCs were added in media
containing peptides selected from T-cell proliferation assay at 37⁰C overnight. Ten
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microgram per ml Concanavalin A and PRRSV FL-12 strain (106.78 TCID50 in infected
cell homogenate) were used as positive controls to validate the gamma interferon
responsiveness of the cells cultured with peptides. Plates were incubated at 37°C
overnight. The plate was washed six times with PBS-Tween20 0.05% (sterile). Then,
100μl secondary antibody (biotin P2C11; BD Biosciences Pharmingen) at 2μg per ml
concentration was added to each well and incubated at 4⁰C overnight. The plate was
washed six times with sterile PBS-Tween20 (0.05%) and incubated at 4⁰C for 45 minutes
after adding 100μl streptavidin alkaline phosphatase (Southern Biotech; cat. # 7100-04)
dissolved in PBS-BSA1% in 1:1000 dilutions. Subsequently, the plate was washed three
times with sterile PBS-Tween20 (0.05%) followed by three washes with PBS. 100μl
alkaline phosphatase substrate (Vector laboratories; cat. # SK-5300) was added to each
well and kept at room temperature for 7-10 minutes. To stop further spot development,
the plate was then washed extensively under running water to stop further spot
development. The number of spot forming cells (SFCs) was counted using the C.T.L
ELISpot machine. These experiments were repeated at least three times for NSP 9, NSP
10 and NSP 11. This assay was performed using both cryopreserved cells and fresh
PBMCs isolated at different time points and repeated at least three times.
Determination of degree of conservation of epitopes
ORF 1b nucleotide sequences from a diverse sample of type-II PRRSV isolates (n=34)
obtained from NCBI database were translated and aligned using CLUSTALW
(http://www.ebi.ac.uk/Tools/msa/clustalw2/). Regions of ORF1b homologous to peptides
containing candidate T-cell epitopes were identified. WebLogo bioinformatics tool was
also used to show the graphical representation of the multiple sequence alignment
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performed for all the 34 NA sequences (Crooks et al., 2004; Schneider and Stephens,
1990). Moreover, ORF 1b nucleotide sequences from a diverse sample of type-II PRRSV
isolates (n=65, Genbank accession numbers pending) were translated, aligned using
MUSCLE (Edgar, 2004) and visualized using JALVIEW(Waterhouse et al., 2009).
Regions of ORF1b homologous to peptides containing candidate T-cell epitopes were
identified and the proportion of PRRSV isolates containing sequences identical to those
of the peptide determined as an indicator of conservation within this sample of PRRSV
isolates.
Bioinformatics approach
All the three proteins of the PRRSV, namely NSP 9, NSP 10 and NSP 11 were analyzed
for the MHC class I and MHC class II-peptide binding prediction tools. BIMAS was
used to analyze CTL epitope by binding to the selected overlapping peptides against 33
human alleles present in its database (Parker et al., 1994). The binding affinity (T1/2
value) depends on the half-time of dissociation of the β2 micro globulin from HLA. A
cutoff T1/2 value of ≥ 100 minutes as well as <100 minutes were selected for analysis.
SYFPEITHI (Rammensee et al., 1999) and PROPRED (Singh and Raghava, 2001) are
the other two algorithms used to identify CTL and class II HLA alleles, respectively. The
optimal value for SYFPEITHI (Rammensee et al., 1999) is ≥15 and for PROPRED
(Singh and Raghava, 2001) the threshold percent is recommended in between 1-3%. The
PROPRED threshold percentage was altered differently to check the binding affinity of
the peptides to the MHC class II alleles.
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Chapter 4: Results
Screening of PRRSV NSP 9 and NSP 10 for T-cell epitopes using T-cell
proliferation assay
Twenty peptide pools from NSP 9 were used for the first round of peptide screening
(figure 2). Based on the criteria described in the materials and methods for analysis of
functional assays, four out of twenty NSP 9 peptide pools encompassing amino acid
positions 103-143, 135-175, 199-239 and 519-559 were identified with stimulation
indices at least twice background (Table 2a). As a result of the T-cell proliferation assay
of the individual peptides present in those four NSP 9 peptide pools (figure 3a), it was
found that four peptides beginning with amino acid positions 119, 151, 207 and 519
elicited positive proliferation results (Table 3).
Fourteen peptide pools from NSP 10 were used for the first round of peptide screening
(figure 2b). Two out of fourteen NSP 10 peptide pools, encompassing amino acid
positions 129-169 and 193-233, were identified which elicited positive stimulation
indices (Table 2). As a result of the T-cell proliferation assay of the individual peptides
present in those two NSP 10 peptide pools (figure 3b it was found that two peptides
encompassing amino acid positions 209-225 and 217-233 respectively exhibited positive
stimulation indices (Table 3).
Seven peptide pools from NSP 11 were used for the first round of peptide screening
(figure 2c). Two out of seven peptide pools, encompassing amino acid positions 1-41 and
33-73, respectively exhibited positive stimulation indices (Table 3). The second round of
screening was not performed for NSP 11 due to limited number of cryopreserved vials
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which could be used for one more set of experiment. We used those cryopreserved
PBMCs for IFN-γ secreting ELISpot assay to detect the immunogenic epitopes present in
the NSP 11 PRRSV protein. Another reason to directly opt for this immunogenic assay
was that we have to detect T-cell epitopes from eight peptides present in those two
peptide pools obtained in the first round of screening. Therefore, the one set of
cryopreserved PBMCs were directly used for ELISpot assay, particularly in the case of
NSP 11.
None of the PBMCs isolated from the control pigs responded to the specific peptides
obtained after two rounds of T-cell peptide screening. All the above experiments were
performed using fresh PBMCs except NSP 11 which was performed using cryopreserved
PBMCs.

Identification of PRRSV immunogenic individual peptides from NSP 9, NSP 10 and
NSP 11
Table 4 provides a summary of the results obtained from cryopreserved PBMCs
stimulated with NSP 9, 10 and 11 peptides inducing IFN-γ. Out of 4 NSP 9 peptides
tested (those that gave a positive response in the lymphoproliferation assay), 2 peptides
at amino acid position 119-135 and 151-167 (KEEIALSAQIIQACDIR and
VRGNPERVKGVLQNTRF) showed specific immunospots as compared with their nonimmunized counterparts (Table 4). During this analysis, the remaining two peptides did
not stimulate IFN-γ response in PBMC populations. In case of NSP 10, both the
individual peptides stimulated proliferation of IFN-γ secreting cells at different time
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points (Table 4). The peptide at amino acid position 209-225 (VRILAGGWCPGKNSFLD)
showed significant increase in IFN-γ ELISpot positive cells following stimulation. The
peptide at amino acid position 217-233 (CPGKNSFLDEAAYCNHL) was able to show
specific immunospots following the second booster dose (121 days post-initial infection
and 7 days after second booster). Three out of eight NSP 11 peptides showed significant
IFN-γ secretion. These peptides are located at amino acid position 1-17
(GSSSPLPKVAHNLGFYF),

9-25

(VAHNLGFYFSPDLTQFA)

and

57-73

(VHKYSRACIGAGYMVGP) (Table 4).

Conservation of PRRSV NSP 9, NSP 10 and NSP 11 peptides identified throughout
North American PRRSV Type-II strains
Thirty-four sequences of North American PRRSV isolates obtained from worldwide
locations (source: NCBI databank) were aligned using Clustal W analytical tool. Figure 4
illustrates the conservation of these identified immunodominant peptides obtained from
NSP

9,

NSP

10

and

NSP

11

of

PRRSV.

NSP

9

peptide

sequence

KEEIALSAQIIQACDIR of FL-12 strain at amino acid position 119 was conserved
throughout the North American isolates (figure 4a,b). Two alterations were found at
amino acid positions 122, 126 and 133 (valine for isoleucine, valine/Methylamine for
alanine

and

aspartic

acid

to

glycine).

In

case

of

peptide

sequence

VRGNPERVKGVLQNTRF, six alterations were found at amino acid position 151 (valine
by isoleucine), 154 (asparagine by aspartic acid), 156 (glutamic acid to aspartic acid), 158
(valine by alanine), 161 (valine by leucine) and 163 (glutamine by lysine)(figure 4a).
Conservation

variation

was

also

noted

in

NSP

10

peptide

sequence
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VRILAGGWCPGKNSFLD at amino acid position 211 where isoleucine was replaced by
threonine. In addition, a unique non-conserved region was also noticed in NSP 11 peptide
sequence GSSSPLPKVAHNLGFYF where tyrosine was replaced by histidine at amino
acid position number 16. Similarly, in case of the other two peptide sequences of NSP 11
amino acid replacement could also be seen (figure 4a). A graphical representation of the
T-cell epitopes from PRRSV NSPs 9, 10 and 11 showing 90-95% conservation pattern
among 34 NA sequences of PRRSV has been represented in figure 4b.

Table 6 illustrates the conservation of these identified NSP 9, NSP 10 and NSP 11
peptides in a sample of diverse PRRSV field isolates. The NSP 9 peptide sequence of FL12 strain at amino acid position 119 was conserved in 22 % of the strains throughout the
North American isolates (Table 6). Unlike, the second epitope at amino acid position 151
found in NSP 9 sequence was conserved in 84% of the 65 NA-PRRSV sequences
analyzed. In case of NSP 10, two T-cell epitopes at amino acid positions 209 and 217
were found to be 95% and 96% conserved, respectively (Table 6). Similarly, NSP 11 Tcell epitopes at amino acid positions 1, 9 and 57 were found to be 96%, 92% and 20%
conserved, respectively (Table 6).

Binding specificity of peptides to HLA class I and II molecules predicted by various
algorithms

The HLA-peptide binding analysis of PRRSV NSPs 9, 10 and 11 have been carried out at
various binding affinities (BIMAS-T1/21-100 minutes; SYFPEITHI-score ≥15 and
PROPRED threshold percentage >3%). The peptides showing both proliferation and
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immunogenicity properties were selected for such an analysis and have been shown in the
Table 5. It was found that one out of two NSP 9 peptides, one out of two NSP 10 peptides
and two out of three NSP 11 peptides were able to show good binding affinity in all the
three algorithms used. Three peptides showed distinct results by not binding to any of the
HLAs present in at least one of the three different algorithms used in this study. NSP 9
peptide at amino acid position 119 could only bind MHC alleles at a low T1/2 value (1-50
minutes). It showed, however, good HLA binding affinity by using SYFPEITHI as well
as PROPRED at their desired optimum values. Similarly, binding specificity of NSP 10
peptide at amino acid position 217 to MHC class II alleles could be seen only above the
threshold value (10%). NSP 11 peptide at amino acid position 1 was unable to bind to
both BIMAS and PROPRED at their proposed optimum values. Moreover, it showed
binding affinity to the MHC class I and II alleles at a lower T1/2 value (1-20 minutes) in
BIMAS and 7% threshold value using PROPRED (Table 5). Altogether, these results
suggest a good correlation link between the bioinformatics approach and functional
assays performed.
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Chapter 5: Discussion
Both neutralizing antibodies and CMI contribute towards the establishment of PRRSV
protective immunity (Kimman et al., 2009; Lopez and Osorio, 2004). While the
mechanisms and viral determinants of protective immunity against PRRSV are
incompletely characterized, protection likely results from recognition of viral epitopes by
both antibodies and T-cells. Identification of T-cell epitopes mediating heterologous
protection, and the nature of variation in those epitopes will directly enhance prediction
of vaccine efficacy and guide the rational design or selection of broadly protective
vaccines through estimation of the optimal composition of epitopes for the formulation of
vaccines efficacious against the majority of PRRSV strains. This would represent a
significant advance in the control of PRRSV. Our present report deals with functional Tcell epitope mapping focused on selected nonstructural PRRSV proteins. These NSPs
constitute fundamental, highly conserved proteins used for the early stages of viral
replication.
The strictly functional approach that we followed in this study has been based on two
bonafide CMI assays: lymphocyte proliferation and frequency of IFN-γ secreting cells. It
has been reported that lymphocyte proliferation from PRRSV-infected pigs can be
detected starting at 4 weeks PI (Bautista and Molitor, 1997; Lopez Fuertes et al., 1999).
Those proliferating cells can also secrete IFN-γ and hence, T-cell response measured by
IFN-γ secreting cell frequency has been shown to be central in clearing viral infections
(Callan et al., 1996; Gruters et al., 2002; Martin et al., 2004; Riddell et al., 1991; Riddell
et al., 1992).
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The emphasis on PRRSV T-cell epitope research and identification has centered, until
now, exclusively on important structural components of this virus. Several papers have
been published suggesting the existence of T-cell epitopes in GP5 (Diaz et al., 2009;
Vashisht et al., 2008), GP4 (Diaz et al., 2009), N (Diaz et al., 2009) and M protein (Wang
et al., 2011). In our case we selected three PRRSV NSPs ( NSP 9,the RdRp, NSP 10, a
helicase and NSP 11, a endonuclease) based on their functional role in viral replication
and virulence, (Fang and Snijder, 2010). NSP 9, NSP 10 and NSP 11 seem to be highly
conserved, being consistent throughout the North American PRRSV strains, thus
constituting good tentative candidates for T-cell epitope mapping to provide crossprotection immunity against PRRSV infection.
Our present report deals with functional epitope mapping focused on selected
nonstructural PRRSV proteins. These NSPs constitute fundamental, highly conserved
proteins used for the early stages of viral replication. The conservation of the identified
epitopes was investigated by aligning amino acid sequences of the NSP 9, NSP 10 and
NSP 11 of North American genotype-II PRRSV strains. Considering the above points,
our data suggests that T-cell epitope amino acid sequence identity is 91% in NSP 9
(amino acid position 119), 79% in NSP 9 (amino acid position 151), 100% in NSP 10
(amino acid position 209 and 217), 94% in NSP 11 (amino acid position 1), 88% in NSP
11 (amino acid position 9) and 79% in NSP 11 (amino acid position 57) (figure 4). Also,
the conservation of the identified epitopes was investigated by aligning sixty-five amino
acid sequences of the NSP 9, NSP 10 and NSP 11 of North American genotype-II
PRRSV strains. Considering the above points, our data suggests that the T-cell epitopes
herein identified range in amino acid sequence identity among 22% in NSP9 (amino acid
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position 119), 84% in NSP 9 (amino acid position 151), 95% in NSP 10 (amino acid
position 209), 97% in NSP 10 (amino acid position 217), 96% in NSP 11 (amino acid
position 1), 92% in NSP 11 (amino acid position 9) and 20% in NSP 11 (amino acid
position 57) (Table 6). From these results, we can confirm that even though these
epitopes are not absolutely conserved, they remain conserved in most of the North
American isolates except for a few mutations in a very low percentage of the strains.
The virus used in our study is the PRRSV FL-12, a highly pathogenic strain derived from
an infectious clone constructed upon parental strain NVSL 97-7895, which belongs to
North American type-II genotype (Truong et al., 2004). Pigs were infected with the
PRRV FL-12 and PBMCs obtained from those pigs were used to analyze synthetic
peptides from NSP 9, NSP 10 and NSP 11. From the present data we cannot infer which
type of cells, within the reacting PBMCs (i.e. CD4+ vs. CD8+ T-cells) are actually
responding to these peptides. Future studies oriented towards such identification would
contribute to a more complete understanding on the specific mechanisms on which the
development of future vaccines should rely.
An important aspect of this preliminary T-cell epitope identification is the immunogenic
character of these epitopes, which has been confirmed by ELISpot. In most cases, the
ELISpot results (Table 4) were obtained only after the first or second booster inoculations
following the initial infection with PRRSV FL-12. It has been shown that the amount of
IFN-γ produced per T-cell against PRRSV is low during the first few weeks after
immunization or infection with PRRSV, although it gradually increases significantly after
3-4 months post-vaccination (Meier et al., 2003; Zuckermann et al., 2007). Evidence for a
role of CMI in protective immunity against PRRSV has been reported by studies in which
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a correlation was found between the IFN-γ response and protective immunity (Meier et
al., 2003; Zuckermann et al., 2007).

We have previously reported that the IFN-γ

response can be used as an indicator of protective immunity and emphasized that in
certain cases the post-challenge recall kinetics of serum neutralizing antibodies does not
correlate with protection(Zuckermann et al., 2007). Similarly, others have concluded that
the presence of virus-specific IFN-γ-secreting T-cell response indicates that vaccination
has elicited protective immunity (Diaz et al., 2006; Martelli et al., 2009).
Overall the IFN-γ response observed with these two sets of peptides would represent a
recall response mediated by PRRSV-specific memory T-cells (Vashisht et al., 2008). The
peptides were synthesized with high purity which explains that the strong reactivity to
these peptides was not due to any kind of contamination; rather, it represents PRRSV
NSP 9, NSP 10 and NSP 11 immunogenic epitopes. The mean ± standard deviation
criterion provides a positive feedback for selecting the peptides with certain cut-off
values thereby restricting the selection of the immunodominant T-cell epitopes.
Unpublished data from our laboratory have shown that cryopreserved PBMCs and
PBMCs extracted from fresh blood exhibit similar activity in ELISpot assays. Although
the magnitude of the immune response was different with different peptides, the
quantitative results remain truly identical. The different PBMCs used for the comparative
ELISpot studies were obtained during the same course of experiments reported here. The
PBMCs were cryopreserved at different time points and the results shown in Table 4 are
a compiled version of all of them. A thorough and consistent report has been obtained
throughout the ELISpot experimental analysis.
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The reports of PRRSV T-cell epitopes existing in the literature include different
approaches ranging from primarily bioinformatics discovery using algorithms for
prediction of T-cell epitopes (Diaz et al., 2009) to those that, like the one herein
described, predominantly map T-cell epitopes by scanning of overlapping peptides along
the protein sequence and assessing their activity in functional assays (Vashisht et al.,
2008; Wang et al., 2011).
It could be argued that false positive and negative results might occur due to the usage of
elevated peptide concentrations to stimulate PBMCs in our experimental study
(10µg/ml).

However, the concentration we used is well within the range of

recommended peptide concentration for T-cell epitope mapping and is consistent with
those commonly used and reported in recent literature (Assarsson et al., 2008; Dow et al.,
2008; Gerner et al., 2009; Haghighi et al., 2009; Streeck et al., 2009; Wulf et al., 2009).
False positive peptides are readily excluded by subsequent confirmatory tests. False
negatives are reduced by designing pools such that each peptide is contained in more than
one pool, minimizing the probability that highly avid peptides will outcompete any
individual peptide (Hoffmeister et al., 2003).
ELISpot assay has proved to be a cost-effective technique to detect T-cell epitopes in
various viral diseases (Streeck et al., 2009). It should be born in mind, however, that the
relationship between the SLA class I and II haplotypes, and the IFN-γ secretion against
PRRSV has also not yet been characterized so far. Future studies should focus on the
characterization, not only of the type of T-cell prevailing in this epitope stimulation, but
also on the characterization of the SLA haplotypes involved in this response. It should be
noted that the response that we measured against individual peptides has been observed,
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in the best case in ≤ 50 % of the animals (Tables 3 and 4). This is might be expected,
given the known polymorphism of the SLA and the fact that pigs used in these
experiments, though from a similar genetic background, were of unknown SLA
haplotypes.
Taken together, we have identified T-cell epitopes present in the NSP 9, NSP 10 and NSP
11 proteins of PRRSV based on their functional and structural constraints. These proteins
were able to show significant T-cell proliferation as well as IFN-γ secretion. The degree
of conservation of these epitopes suggests that they may be highly useful in the rational
design of broadly efficacious vaccines against PRRSV.

Table1. Name of the peptide pools and individual peptides used for T-cell
proliferation and ELISpot assays.

Peptide pool no.

I

II

III

IV

V

VI

VII

VIII

IX

X

7-23

39-55

71-87

103-119

135-151

167-183

199-215

231-247

263-279

295-311
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15-31

47-63

79-95

111-127

143-159

175-191

207-223

239-255

271-287

303-319

23-39

55-71

87-103

119-135

151-167

183-199

215-231

247-263

279-295

311-327

31-47

63-79

95-111

127-143

159-175

191-207

223-239

255-271

287-303

319-335

XI

XII

XIII

XIV

XV

XVI

XVII

XVIII

XIX

XX

327-343

359-375

391-407

423-439

455-471

487-503

519-535

551-567

583-599

615-631

335-351

367-383

399-415

431-447

463-479

495-511

527-543

559-575

591-607

623-639

343-359

375-391

407-423

439-455

471-487

503-519

535-551

567-583

599-615

631-646

351-367

383-399

415-431

447-463

479-495

511-527

543-559

575-591

607-623

I

II

III

IV

V

VI

VII

VIII

IX

Peptide pool no.

X

1-17

33-49

65-81

97-113

129-145

161-177

193-209

225-241

257-273

289-305

9-25

41-57

73-89

105-121

137-153

169-185

201-217

233-249

265-281

297-313

17-33

49-65

81-97

113-129

145-161

177-193

209-225

241-257

273-289

305-321

25-41

57-73

89-105

121-137

153-169

185-201

217-233

249-265

281-297

313-329

XII

XIII

XIV

321-337

XI

353-369

385-401

417-433

329-345

361-377

393-409

425-441

337-353

369-385

401-417

345-361

377-393

409-425

I

Peptide pool no.

II

III

IV

V

VI

VII

1-17

33-49

65-81

97-113

129-145

161-177

193-209

9-25

41-57

73-89

105-123

137-153

169-185

201-217

17-33

49-65

81-97

113-129

145-161

177-193

209-225

25-41

57-73

89-105

121-137

153-169

185-201
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Table 2. Identification of peptide pools using lymphoproliferative [H3] incorporation assay.
protein
name
NSP 9

NSP 10

NSP 11

peptide
pool no.

overlapping aa sequence in a peptide pool

no. of resp.
pigs for each
peptide pool

IV

NTGIDGTLWDFEAEATKEEIALSAQIIQACDIRRGDAPEIG

3\8

V

RRGDAPEIGLPYKLYPVRGNPERVKGVLQNTRFGDIPYKTP

1\8

VII

RSVLATTMPSGFELYVPTIPASVLDYLDSRPDCPKQLTEHG

1\8

XVII

ESPTMPNYHWWVEHLNLMLGFQTDPKKTAITDSPSFLGCRI

1\8

V

CKEINMVAVASNVLRSRFIIGPPGAGKTYWLLQQVQDGDVI

4\4

VII

AGTTLQFPAPSRTGPWVRILAGGWCPGKNSFLDEAAYCNHL

3\4

I

GSSSPLPKVAHNLGFYFSPDLTQFAKLPVELAPHWPVVTTQ

1\4

II

PHWPVVTTQNNEKWPDRLVASLRPVHKYSRACIGAGYMVGP

1\4

Notes: Pigs in the principal group were inoculated with PRRSV FL-12 and blood samples
were collected starting at 7 d.p.i. The results shown here is the average of the PBMCs
collected on 14 d.p.i., 21 d.p.i. and 28 d.p.i. This table shows the nine amino acid
overlapping sequence length of peptide pools identified from PRRSV NSP 9, 10 and 11
at their respective amino acid positions after the first round of T-cell epitope mapping.
The number of responding pigs is the immunized animals whose PBMC exhibited a
peptide-specific proliferation with a stimulation index ≥ 2 along with a zero background
response. The response to the peptides had to be ≥ 2 than the proliferated cells of nonimmunized control pigs to be considered positive. None of the PBMCs samples isolated
from the control pigs responded to the peptides pools herein shown.
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Table 3. Identification of heptadecamer PRRSV peptides likely to contain of NSP 9 and
NSP 10 epitopes.
no. of resp. pigs for
each individual
protein name
peptide name
peptide sequence
peptide
KEEIALSAQIIQACDIR
NSP 9
119-135
4\8
VRGNPERVKGVLQNTRF
151-167
2\8
PSGFELYVPTIPASVLD
207-223
1\8
ESPTMPNYHWWVEHLNL
519-535
2\8
NSP 10

209-225
217-233

VRILAGGWCPGKNSFLD
CPGKNSFLDEAAYCNHL

2\4
2\4

Notes: Pigs in the principal group were inoculated with PRRSV FL-12 and blood samples
were collected 7 days post first booster dose (boosters were applied at 21 d.p.i for NSP 9
study and at 57 d.p.i for NSP 10 study). This table shows the heptadecamer sequence
length of the individual peptides identified from PRRSV NSP 9 and 10 at their respective
amino acid positions after the second round of T-cell epitope mapping. The number of
responding pigs is the immunized animals whose PBMC exhibited a peptide-specific
proliferation with a stimulation index ≥ 2 along with a zero background response. The
response to the peptides had to be ≥ 2 than the proliferated cells of non-immunized pigs
to be considered positive. None of the PBMCs samples isolated from the non-immunized
control pigs responded to any of these individual peptides.
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Table 4. T-cell epitopes in PRRSV NSP 9, NSP 10 and NSP 11 identified by the IFN-γ induction
criteria.
d

tot. resp
10.6
5.3
9
3

avg.
resp
1.7
0.8
1.5
0.5

no.
resp.
pigs
2\8
2\8
1\8
2\8

7.3
27.3

4.3
33.9

1.0
8.4

1\4
2\4

14
21.2

37.33
40
39.66

63.99
48.99
63.33

21.33
16.33
21.11

1\4
1\4
1\4

65
67.67
65.33

a

Protein
name
NSP 9
NSP 9
NSP 9
NSP 9

aa
position
119-135
151-167
207-223
519-535

peptide sequence
KEEIALSAQIIQACDIR
VRGNPERVKGVLQNTRF
PSGFELYVPTIPASVLD
ESPTMPNYHWWVEHLNL

max.
resp
8
8. 6
3.7
2.7

NSP 10
NSP 10

209-225
217-233

VRILAGGWCPGKNSFLD
CPGKNSFLDEAAYCNHL

NSP 11
NSP 11
NSP 11

1-17
9-25
57-73

GSSSPLPKVAHNLGFYF
VAHNLGFYFSPDLTQFA
VHKYSRACIGAGYMVGP

c
b

e

avg. resp
pigs
12.8
8.5
0.7
4.7

Notes: Pigs were initially infected with PRRSV FL-12 and subsequently were
administered two additional boosters (at 21 d.p.i and 96 d.p.i for the NSP 9 experiment,
and at 57 and 114 d.p.i for the NSP 10 and NSP 11 experiments. The ELISpot results
shown here is the compilation of data obtained from the interferon response from the
PBMCs cryopreserved at different time points post first and second booster doses. The
ELISpot experiments for each protein were performed independently.
a

Max.resp: number of IFN-producing cells detected in PBMC from the highest
responder pig among all 2 PBMC samples tested.
b
Tot.resp: sum of all of the IFN-producing cells (minus background) detected in
the 2 individually tested PBMC samples.
c
Avg. resp: sum of all the IFN-producing cells (minus background) detected in the
2 PBMC samples tested divided by 2, the number of pigs tested.
d
No. Resp. pigs: number of pigs exhibiting a frequency of peptide-specific IFN-γ
secreting cells with a stimulation index ≥ 2 than the cells only. If background
response was zero the response to the peptide had to be ≥2 to be considered
positive.
e
Avg Resp pigs: average of the peptide-specific IFN-specific IFN-response
(minus background) of all the pigs exhibiting a response to the individual peptide.
f
Mean±Std.D: mean ± standard deviation of the values shown for each of the four
T-cell peptide candidate for each of the selection criteria were concluded to
contain an immunodominant peptide (Vashisht et al., 2008).
Peptide sequences in bold represent the positive peptides which showed maximum IFN-γ
secretion. Controls used in this assay were: concanavalin A (positive control), FL-12
infected cell homogenates (positive control) and PBMCs only, without peptide (negative
control). None of these peptides reacted with the PBMCs of the non-immunized control
pigs (mean ± std.dev. = 0±3).
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Table 5. Feasibility of PRRSV nonstructural proteins to HLA using various peptide
prediction tools at different threshold values.
Protein

aa

name

posn.

BIMAS

At

NSP9

NSP10

NSP11

SYFPEITHI

low

PROPRED
Threshold

Above

T1/2(<100)

At T1/2(≥100)

score ≥15

(1-3%)

threshold

119

+++

no

+++

+

-

151

+++

++

+++

+++

-

209

+++

+

+++

+++

-

217

+++

+

++

no

+

1

+++

no

+++

no

+

9

+++

++

+++

+++

-

57

+++

++

+++

+++

-

Note: Plus sign represents the different HLA alleles bound to T-cell epitopes obtained
from PRRSV NSPs 9, 10 and 11. ‘+’=one allele; ‘++’=2-3 alleles; ‘+++’=3 or more
alleles; ‘no’=no alleles binding.
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Table 6. Conserved T-cell epitopes in NSP 9, NSP 10 and NSP 11.

Sequence
NSP 9 (119-135)
KEEVALSAQIIQACDIR
KEEIALSAQIIQACDIR
KEEIALSAQIIQACGIR
KEEIALSAQIIQACDMR
KEEVALSAQIIQACDMR
KEEVALSAQIIQACGIR
KEEIELSAQIIQACGIR
KEEIALSTQIIQACDIR
KEEIALSAQIIQACSIR
KEEIALSEQIIQACDIR
KEEVALSTQIIQACDIR
NSP 9 (151-167)
VRGNPERVKGVLQNTRF
IRGNPERVKGVLRNTRF
VRDNPERVKGVLKNTRF
VRGDPERVKGVLKNTRF
VRGNPERARGVLMNTRF
VRGNPERVNGVLQNTRF
VRGNPERVKGVLRNTRF
VRGNPERVKGVLKNTRF
NSP 10 (209-225)
VRILAGGWCPGKNSFLD
VRILAGGWCPGRNSFLD
VRILAGRWCPGKNSFLD
NSP 10 (217-233)
CPGKNSFLDEAAYCNHL
CPGRNSFLDEAAYCNHL
NSP 11 (1-17)
GSSSPLPKVAHNLGFYF
NSP 11 (9-25)
VAHNLGFYFSPDLTQFA
VAHNLGFYFSPDLIQFA
VAHNLGFYFSPDLAQFA
NSP 11 (57-73)
VHKYSRACIGAGYMVGP

Count

*Proportion

28
14
8
5
2
2
2
1
1
1
1

0.43
0.22
0.12
0.08
0.03
0.03
0.03
0.02
0.02
0.02
0.02

55
1
1
1
1
2
3
1

0.8461538
0.0153846
0.0153846
0.0153846
0.0153846
0.0307692
0.0461538
0.0153846

62
2
1

0.9538462
0.0307692
0.0153846

63
2

0.9692308
0.0307692

63

0.96923077

60
2
1

0.92307692
0.03076923
0.01538462

13

0.2

48
IHKYSRACIGAGYMVGP
IHKHSRACVGAGYMVGP
IHKHSRACIGAGYMVGP
IHKYSRACVGAGYMVGP
IHNYSRACIGAGYMVGP

44
2
2
1
1

0.67692308
0.03076923
0.03076923
0.01538462
0.01538462

Notes: Sequences in bold define the T-cell epitopes obtained in our study after stringent
categorization of the heptadecamer peptides present in NSP 9, NSP 10 and NSP 11. Other
heptadecamer sequences were considered from various other PRRSV isolates among the
65 sequences aligned. The count number denotes the number of identical sequences out
of 65 sequences aligned using JALVIEW. *Proportion of the sequence represents the
conservation of those T-cell epitopes by applying the following formula:
no. of count of similar sequences/total no. of sequences used for multiple alignment.
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Figure 1

50

Figure 2
(a)

(b)

51

(c)

52

Figure 3
(a)

(b)

53

Figure 4
(a)

Notes: Sequence accession number in bold red defines the PRRSV virulent strain (FL-12)
used in our study to determine T-cell epitopes after stringent categorization of the
heptadecamer peptides present in NSP 9, NSP 10 and NSP 11. Other heptadecamer
sequences were considered from various other NA-PRRSV isolates among the 34
sequences aligned. The bold letters in red denotes the amino acid variations observed in
the different PRRSV sequences used for the multiple sequence alignment.
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(b)

Note: Graphical representation showing conservation of the seven T-cell epitopes
obtained from NSP 9, 10 and 11 by performing multiple sequence alignment via weblogo
bioinformatics tool. The amino acids which reach 4 bits on the y-scale are highly
conserved whereas the one which are lower than that are conserved with a lower
percentage.
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